Dimensional Fund Advisors LP Buys 69,848 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Dimensional Fund Advisors LP raised its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 48.6% in the 2nd quarter, Holdings Channel.com reports. The firm owned 213,619 shares of the biotechnology company’s stock after acquiring an additional 69,848 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Ironwood Pharmaceuticals were worth $1,393,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of IRWD. PNC Financial Services Group Inc. grew its stake in shares of Ironwood Pharmaceuticals by 152.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 2,645 shares during the period. CWM LLC increased its stake in shares of Ironwood Pharmaceuticals by 55.1% in the second quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 2,345 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Ironwood Pharmaceuticals in the first quarter valued at approximately $91,000. GAMMA Investing LLC raised its position in shares of Ironwood Pharmaceuticals by 344.1% in the second quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 8,156 shares during the period. Finally, EntryPoint Capital LLC lifted its stake in shares of Ironwood Pharmaceuticals by 517.4% during the 1st quarter. EntryPoint Capital LLC now owns 10,589 shares of the biotechnology company’s stock valued at $92,000 after buying an additional 8,874 shares in the last quarter.

Ironwood Pharmaceuticals Stock Performance

NASDAQ:IRWD opened at $4.26 on Friday. Ironwood Pharmaceuticals, Inc. has a 52-week low of $3.79 and a 52-week high of $15.70. The stock has a fifty day moving average of $4.55 and a 200 day moving average of $6.14. The firm has a market capitalization of $666.81 million, a price-to-earnings ratio of -0.63 and a beta of 0.48.

Analyst Ratings Changes

A number of research firms recently weighed in on IRWD. Wells Fargo & Company lowered their target price on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, August 9th. StockNews.com upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 16th. Capital One Financial cut Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $12.00 to $4.00 in a report on Thursday, August 8th. Leerink Partnrs raised Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. Finally, Leerink Partners began coverage on Ironwood Pharmaceuticals in a research report on Monday, September 9th. They set a “market perform” rating and a $5.00 price target on the stock. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $12.17.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other news, insider Minardo John sold 9,910 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $4.27, for a total transaction of $42,315.70. Following the completion of the transaction, the insider now owns 284,661 shares of the company’s stock, valued at approximately $1,215,502.47. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 12.90% of the company’s stock.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.